钠-葡萄糖协同转运蛋白2抑制剂治疗糖尿病合并冠心病及心力衰竭的研究进展  

Research progress of SGLT2i in the treatment of diabetes mellitus combined with coronary heart disease and heart failure

作　　者：张家瑞 黄李晨露 吴文哲 郑永钦[2] 贺军栋[2] ZHANG Jiarui;HUANG Lichenlu;WU Wenzhe(Medical School,Kunming University of Science and Technology,Kunming 650500,China)

机构地区：[1]昆明理工大学医学院,650500 [2]云南省第一人民医院内分泌代谢科

出　　处：《中国糖尿病杂志》2022年第12期941-944,共4页Chinese Journal of Diabetes

基　　金：云南省临床医学中心开放课题(2021LCZXXF-NM04);云南省中青年学术和技术带头人后备人才(2018HB050);云南省万人计划青年拔尖人才(YNWR-QNBJ-2018-070)。

摘　　要：DM是威胁人类健康的慢性病。冠心病(CHD)是T2DM患者常见并发症,心血管疾病是DM患者主要死因。肾近曲小管S1和S2部位内壁细胞膜上发现SGLT2,是参与葡萄糖重吸收的重要转运蛋白,也是T2DM靶向治疗的关键蛋白。SGLT2i类药物可降低DM合并CHD及心力衰竭(HF)发病率和死亡风险。本文对SGLT2i治疗DM合并CHD及HF的研究进展进行综述。Diabetes mellitus(DM)is a chronic disease threatening human health. Coronary heart disease(CHD)is a common complication in patients with T2DM,and cardiovascular disease(CVD)is the main cause of death in patients with T2DM. Sodium-glucose co-transporter 2(SGLT2)is found on the inner wall cell membrane of proximal convoluted tubules S1 and S2,which is an important transporter involved in glucose reabsorption and a key protein for targeted treatment of T2DM. SGLT2i drugs can reduce the incidence rate and death risk of DM with CHD and heart failure(HR). This article reviews the research progress of SGLT2i in the treatment of DM with CHD and HR.

关 键 词：钠-葡萄糖协同转运蛋白2抑制剂 糖尿病 2型 冠心病 心力衰竭 

分 类 号：R587.1[医药卫生—内分泌] R541.4[医药卫生—内科学] R541.6[医药卫生—临床医学]